1. Home
  2. SPRO vs AMWL Comparison

SPRO vs AMWL Comparison

Compare SPRO & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • AMWL
  • Stock Information
  • Founded
  • SPRO 2013
  • AMWL 2006
  • Country
  • SPRO United States
  • AMWL United States
  • Employees
  • SPRO N/A
  • AMWL N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • AMWL Retail: Computer Software & Peripheral Equipment
  • Sector
  • SPRO Health Care
  • AMWL Technology
  • Exchange
  • SPRO Nasdaq
  • AMWL Nasdaq
  • Market Cap
  • SPRO 121.0M
  • AMWL 111.4M
  • IPO Year
  • SPRO 2017
  • AMWL 2020
  • Fundamental
  • Price
  • SPRO $1.90
  • AMWL $6.49
  • Analyst Decision
  • SPRO Buy
  • AMWL Hold
  • Analyst Count
  • SPRO 4
  • AMWL 7
  • Target Price
  • SPRO $5.00
  • AMWL $9.17
  • AVG Volume (30 Days)
  • SPRO 323.5K
  • AMWL 52.0K
  • Earning Date
  • SPRO 11-13-2025
  • AMWL 10-29-2025
  • Dividend Yield
  • SPRO N/A
  • AMWL N/A
  • EPS Growth
  • SPRO N/A
  • AMWL N/A
  • EPS
  • SPRO N/A
  • AMWL N/A
  • Revenue
  • SPRO $48,576,000.00
  • AMWL $269,783,000.00
  • Revenue This Year
  • SPRO N/A
  • AMWL N/A
  • Revenue Next Year
  • SPRO N/A
  • AMWL $3.10
  • P/E Ratio
  • SPRO N/A
  • AMWL N/A
  • Revenue Growth
  • SPRO N/A
  • AMWL 5.83
  • 52 Week Low
  • SPRO $0.51
  • AMWL $6.10
  • 52 Week High
  • SPRO $3.22
  • AMWL $12.95
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 40.19
  • AMWL 38.67
  • Support Level
  • SPRO $1.91
  • AMWL $6.46
  • Resistance Level
  • SPRO $2.18
  • AMWL $6.68
  • Average True Range (ATR)
  • SPRO 0.09
  • AMWL 0.24
  • MACD
  • SPRO 0.00
  • AMWL -0.01
  • Stochastic Oscillator
  • SPRO 11.94
  • AMWL 4.88

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About AMWL American Well Corporation

American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.

Share on Social Networks: